Distinguished in Plaque Psoriasis

Dr. Cindy Owen

Dermatology
Associates In Dermatology PLLC
3810 Springhurst Blvd Ste 200, 
Louisville, KY 
Distinguished in Plaque Psoriasis
Associates In Dermatology PLLC
3810 Springhurst Blvd Ste 200, 
Louisville, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Cindy Owen is a Dermatologist in Louisville, Kentucky. Dr. Owen is rated as a Distinguished provider by MediFind in the treatment of Plaque Psoriasis. Her top areas of expertise are Plaque Psoriasis, Psoriasis, Eosinophilic Pustular Folliculitis, and Giant Congenital Melanocytic Nevus.

Her clinical research consists of co-authoring 16 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 4 clinical trials in the study of Plaque Psoriasis.

Specialties
Dermatology
Licenses
Dermatology in KY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Associates In Dermatology PLLC
3810 Springhurst Blvd Ste 200, Louisville, KY 40241
Call: 502-583-1749
Other Locations
University Medical Center Inc
530 S Jackson St, Louisville, KY 40202
Call: 502-583-1749

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata
A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Biological
Study Phase: Phase 2
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 12 Less Clinical Trials

16 Total Publications

Acute cryoglobulinemic vasculitis following rituximab infusion for waldenström macroglobulinemia.
Acute cryoglobulinemic vasculitis following rituximab infusion for waldenström macroglobulinemia.
Journal: JAAD case reports
Published: April 10, 2023
View All 16 Publications
Similar Doctors
Distinguished in Plaque Psoriasis
Dr. Stephen Smith
Dermatology
Distinguished in Plaque Psoriasis
Dr. Stephen Smith
Dermatology

Hoagland & Figert PLLC

3950 Kresge Way Ste 404, 
Louisville, KY 
 (5.8 miles away)
502-896-8803
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Smith is a Dermatologist in Louisville, Kentucky. Dr. Smith is rated as a Distinguished provider by MediFind in the treatment of Plaque Psoriasis. His top areas of expertise are Squamous Cell Skin Carcinoma, Plaque Psoriasis, Bowen's Disease, and Psoriasis.

Distinguished in Plaque Psoriasis
Dr. Leigh Beard
Dermatology
Distinguished in Plaque Psoriasis
Dr. Leigh Beard
Dermatology

Manoochehr Mazloomdoost PSC

715 Shaker Dr Ste 132, 
Lexington, KY 
 (58.1 miles away)
859-288-5004
Languages Spoken:
English
See accepted insurances

Leigh Beard is a Dermatologist in Lexington, Kentucky. Dr. Beard is rated as an Advanced provider by MediFind in the treatment of Plaque Psoriasis. Her top areas of expertise are Plaque Psoriasis, Psoriasis, Basal Cell Skin Cancer, and Squamous Cell Skin Carcinoma.

Distinguished in Plaque Psoriasis
Dr. John Roth
Dermatology
Distinguished in Plaque Psoriasis
Dr. John Roth
Dermatology

Kentucky Dermatology And Skin Cancer Clinic PSC

177 Burt Rd, 
Lexington, KY 
 (60.1 miles away)
859-276-1511
Languages Spoken:
English
See accepted insurances

John Roth is a Dermatologist in Lexington, Kentucky. Dr. Roth is rated as a Distinguished provider by MediFind in the treatment of Plaque Psoriasis. His top areas of expertise are Actinic Keratosis, Plaque Psoriasis, Basal Cell Skin Cancer, and Warts.

VIEW MORE PLAQUE PSORIASIS DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Owen's expertise for a condition
ConditionClose
    • Distinguished
    • Plaque Psoriasis
      Dr. Owen is
      Distinguished
      . Learn about Plaque Psoriasis.
      See more Plaque Psoriasis experts
    • Advanced
    • Actinic Keratosis
      Dr. Owen is
      Advanced
      . Learn about Actinic Keratosis.
      See more Actinic Keratosis experts
    • Autosomal Recessive Hypotrichosis
      Dr. Owen is
      Advanced
      . Learn about Autosomal Recessive Hypotrichosis.
      See more Autosomal Recessive Hypotrichosis experts
    • Dermatomyositis
      Dr. Owen is
      Advanced
      . Learn about Dermatomyositis.
      See more Dermatomyositis experts
    • Eosinophilic Pustular Folliculitis
      Dr. Owen is
      Advanced
      . Learn about Eosinophilic Pustular Folliculitis.
      See more Eosinophilic Pustular Folliculitis experts
    • Erythema Multiforme
      Dr. Owen is
      Advanced
      . Learn about Erythema Multiforme.
      See more Erythema Multiforme experts
    • Familial Atypical Multiple Mole Melanoma Syndrome
      Dr. Owen is
      Advanced
      . Learn about Familial Atypical Multiple Mole Melanoma Syndrome.
      See more Familial Atypical Multiple Mole Melanoma Syndrome experts
    View All 18 Advanced Conditions
    • Experienced
    • Acanthosis Nigricans
      Dr. Owen is
      Experienced
      . Learn about Acanthosis Nigricans.
      See more Acanthosis Nigricans experts
    • Acromegaloid Facial Appearance Syndrome
      Dr. Owen is
      Experienced
      . Learn about Acromegaloid Facial Appearance Syndrome.
      See more Acromegaloid Facial Appearance Syndrome experts
    • Alopecia Areata
      Dr. Owen is
      Experienced
      . Learn about Alopecia Areata.
      See more Alopecia Areata experts
    • Atopic Dermatitis
      Dr. Owen is
      Experienced
      . Learn about Atopic Dermatitis.
      See more Atopic Dermatitis experts
    • Autoerythrocyte Sensitivity
      Dr. Owen is
      Experienced
      . Learn about Autoerythrocyte Sensitivity.
      See more Autoerythrocyte Sensitivity experts
    • Basal Cell Skin Cancer
      Dr. Owen is
      Experienced
      . Learn about Basal Cell Skin Cancer.
      See more Basal Cell Skin Cancer experts
    View All 82 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.